OSE Immunotherapeutics: Covid-19 CoVepiT Vaccine Generates Hope

OSE Immunotherapeutics generates hope. The Nantes laboratory took stock of the first positive results and the clinical development of CoVepiT, its multi-target anti-Covid T vaccine. New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy vaccinated volunteers. Promising preclinical signs of efficacy are guiding development in immunosuppressed patients with poor antibody responses to COVID vaccines already on the market.

Long-term memory T response results at 6 months, expected in the first quarter of 2022, will be a key element in subsequent clinical development. CoVepiT epitopes remain independent of identified mutations in current and emerging variants. These epitopes, viral protein fragments, are antigenic determinants recognized by T cell receptors during an adaptive T immune response. They are not currently affected by the mutations described for existing (Delta) and emerging (Omicron) variants.

>> Buy and sell your investments (stocks, cryptocurrencies, gold …) at the right time thanks to Momentum, the Capital newsletter on technical analysis. And right now, with the promotion code CAPITAL30J, enjoy a free trial month.

Receive our latest news Every morning, the information to remember financial markets.

WeaPlay, WordPress Theme, Business Consulting Nulled, Avada 7.4 Nulled, Newspaper – News & WooCommerce WordPress Theme, Nulledfire, Elementor Pro Weadown, Astra Pro Nulled, Plugins, Rank Math Seo Pro Weadown, Woodmart Theme Nulled, Elementor Pro Weadown,Woodmart Theme Nulled, Wordfence Premium Nulled, Flatsome Nulled, Yoast Nulled, Woocommerce Custom Product Ad, Jannah Nulled, Dokan Pro Nulled, Fs Poster Plugin Nulled, Jnews 8.1.0 Nulled, PW WooCommerce Gift Cards Pro Nulled, Newspaper 11.2, Premium Addons for Elementor, Slider Revolution Nulled, Wpml Nulled, PHP Script, WP Reset Pro, Consulting 6.1.4 Nulled

Back to top button